🗞 Medical News
Topic: Investigational herbal product lowers HbA1c in T2DM patients (HTD1801 - Novel Metabolic Modulator)
Source : PubMed
Topic: Investigational herbal product lowers HbA1c in T2DM patients (HTD1801 - Novel Metabolic Modulator)
Study Details: A randomized clinical trial evaluated HTD1801 in 113 patients with T2DM. Participants (baseline HbA1c 8.2%) received HTD1801 500 mg BID (n=37), 1000 mg BID (n=38), or placebo (n=38) for 12 weeks. The primary outcome was HbA1c change, with secondary outcomes assessing glycemic, hepatic, and cardiometabolic parameters.
Results:
▪️HbA1c reduction: -0.4% (500 mg, P=0.04) and -0.7% (1000 mg, P